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Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable psychiatric disorders, for which
familial coaggregation, as well as epidemiological and genetic evidence, suggests overlapping etiologies. No deﬁnitive
susceptibility genes have yet been identiﬁed for any of these disorders. Genetic heterogeneity, combined with
phenotypic imprecision and poor marker coverage, has contributed to the difﬁculty in deﬁning risk variants. We
focused on families of Ashkenazi Jewish descent, to reduce genetic heterogeneity, and, as a precursor to genomewide
association studies, we undertook a single-nucleotide polymorphism (SNP) genotyping screen of 64 candidate genes
(440 SNPs) chosen on the basis of previous linkage or of association and/or biological relevance. We genotyped
an average of 6.9 SNPs per gene, with an average density of 1 SNP per 11.9 kb in 323 bipolar I disorder and 274
schizophrenia or schizoaffective Ashkenazi case-parent trios. Using single-SNP and haplotype-based transmission/
disequilibrium tests, we ranked genes on the basis of strength of association ( ). Six genes (DAO, GRM3,P ! .01
GRM4, GRIN2B, IL2RB, and TUBA8) met this criterion for bipolar I disorder; only DAO has been previously
associated with bipolar disorder. Six genes (RGS4, SCA1, GRM4, DPYSL2, NOS1, and GRID1) met this criterion
for schizophrenia or schizoaffective disorder; ﬁve replicate previous associations, and one, GRID1, shows a novel
association with schizophrenia. In addition, six genes (DPYSL2, DTNBP1, G30/G72, GRID1, GRM4, and NOS1)
showed overlapping suggestive evidence of association in both disorders. These results may help to prioritize
candidate genes for future study from among the many suspected/proposed for schizophrenia and bipolar disorders.
They provide further support for shared genetic susceptibility between these two disorders that involve glutamate-
signaling pathways.
Introduction
Bipolar disorders (BP [MIM 125480]) and schizophrenia
(SZ [MIM 181500]) are common and debilitating psy-
chiatric disorders. Among the several forms of BP, bi-
polar 1 (BPI) is the most severe, has the highest interrater
reliability, and is characterized by disabling bouts of ma-
nia and depression (American Psychiatric Association
1994). SZ is a disorder of thought and emotions, char-
acterized by psychotic manifestations, including hallu-
cinations and delusions, lack of motivation, and anhe-
donia. Both SZ and BPI show variable clinical expres-
sion. No symptom or behavior is pathognomic for either
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disorder. In addition, there can be overlap in clinical
presentation (e.g., a majority of individuals with BPI
experience hallucinations or delusions [Goodwin and Ja-
mison 1990; Dunayevich and Keck 2000; Potash et al.
2001]). The schizoaffective disorder (SZA) diagnosis
was developed to help categorize the group of patients
who experienced both affective and SZ-like symptoms.
The utility of this diagnosis remains controversial—that
is, interrater reliability for the SZA disorder tends to be
low, and diagnostic stability is worse than for SZ or BP
(Kempf et al. 2005). In genetic studies, SZA cases are
sometimes included with SZ cases and, other times, with
BP cases (e.g., Lewis et al. 2003; Segurado et al. 2003).
Multiple investigators have reported heritability esti-
mates for SZ and BP, with ranges of 41%–87% for BP
(Tsuang and Faraone 1990) and 70%–85% for SZ
(Tsuang and Faraone 1990; McGue and Gottesman
1991; Tsuang et al. 1991; Cardno et al. 1999, 2001).
Heritability estimates for SZA have been reported to be
similar to those for SZ (Cardno et al. 1999).
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Intensive efforts to localize or identify susceptibility
genes for BPI have yielded neither consensus linkage
regions nor consistent associations with candidate
genes. The two meta-analyses of BPI linkage studies
conducted thus far do not support overlapping linkage
regions: Badner and Gershon (2002) identiﬁed regions
on chromosomes 13q and 22q, whereas Segurado et al.
(2003) identiﬁed regions on chromosomes 9p, 10q, and
14q. Recently, we identiﬁed suggestive linkage to BPI
on chromosomes 1q23, 3p32, 11q12, and 18q22
among Ashkenazi Jewish (AJ) families (Fallin et al.
2004). Several candidate-gene associations for BP have
been reported, but, in general, these have not been rep-
licated, nor have causal variants been identiﬁed (Sklar
et al. 2002; Maier et al. 2003; Hashimoto et al. 2005;
Lasky-Su et al. 2005; Preisig et al. 2005).
By contrast, linkage evidence for an SZ/SZA locus
has been identiﬁed across almost every human chro-
mosome, with notable signals on chromosomes 1q, 6p,
6q, 8p, 13q, and 22q (for review, see Owen et al. 2004).
Two meta-analyses of SZ genome scans do not ﬁnd
exactly overlapping regions, although one found evi-
dence of linkage on chromosomes 8p, 13q, and 22q
(Badner and Gershon 2002), and the other found the
strongest evidence on chromosome 2q, with 15 other
regions noted as important, including 8p and 22q
(Lewis et al. 2003). We reported linkage evidence for
SZ on chromosome 10q22 among 29 multiplex AJ fam-
ilies with SZ/SZA (Fallin et al. 2003). Other studies
show suggestive evidence of linkage to SZ in this region,
although the region is not usually among the highest
signals (Lerer et al. 2003; Park et al. 2004) and was not
identiﬁed in the meta-analyses. Interestingly, Hennah et
al. (2004) found strong linkage to this 10q region for
SZ in a Finnish sample, after conditioning on the dis-
rupted-in-schizophrenia-1 gene (DISC1).
Several candidate genes have shown association with
SZ/SZA, notably regulator of G-protein signaling 4
(RGS4) on chromosome 1q23, DISC1 on chromosome
1q42, dystrobrevin-binding protein 1 (DTNBP1) on
chromosome 6p22, neuregulin 1 (NRG1) on chromo-
some 8p12, G30/G72 on chromosome 13q33, and cat-
echol-O-methyltransferase (COMT) on chromosome
22q11 (Owen et al. 2004). Replication in at least one
independent sample has been reported for each of these,
along with multiple reports of failures to ﬁnd associa-
tion, and no sequence variant predicted to alter function
has been established across populations. We have in-
cluded SNPs for each of these genes in our study.
Several factors have likely contributed to the incon-
sistencies in linkage and association studies of BP and
SZ/SZA, including locus and allelic heterogeneity, dif-
ﬁculties in diagnosis, and limitations in technology and
marker availability that, until recently, have hindered
adequate coverage of candidate genes and regions. To
minimize these problems, we conducted a candidate-
gene study of 440 SNPs in 64 candidate genes, using
DNAs from case-parent trios of AJ descent, 337 with
BPI, 217 with SZ, and 57 with SZA. We focused on
families of AJ descent, to reduce allelic and locus het-
erogeneity, and we used precise and narrow disease def-
initions, such as restricting our BP trios to those with
cases meeting criteria for BPI and considering a com-
bined group of SZ/SZA as well as a restricted SZ-only
set. We have taken advantage of more-affordable mul-
tiplex genotyping technology (Illumina Bead Array), as
well as the emerging public SNP information, to achieve
greater coverage of variation for a relatively large list
of candidate genes, compared with previous candidate
gene studies for BP or SZ, in the hope of increasing the
potential to detect associations. Although the ultimate
goal is to genotype the entire human genome to search
for susceptibility, this candidate gene strategy has been
advocated by others (Sklar et al. 2002; Botstein and
Risch 2003) as a quick and efﬁcient approach with the
possibility of early success.
Methods
Recruitment
Over a 6-year period, we recruited individuals of AJ
descent with BPI and SZ/SZA through advertisements
in newspapers and Jewish newsletters, talks to com-
munity organizations, letters to leaders of the Jewish
community, letters and talks to service providers, and a
study Web site hosted by the Johns Hopkins Epidemi-
ology-Genetics Program in Psychiatry. Case-parent trios
were eligible for inclusion in these analyses if the pro-
band met criteria for either a BPI diagnosis or an SZ or
SZA diagnosis, according to the DSM-IV (American Psy-
chiatric Association 1994), if both parents were avail-
able for DNA collection, and if four grandparents were
known to be of AJ descent. All recruitment methods and
protocols for the collection of blood samples and clinical
data were approved by the Johns Hopkins institutional
review board, and appropriate informed consent was
obtained from all human subjects.
Diagnostic Instruments and Procedures
The data collection for this study was done in tandem
for studies of BPI and SZ/SZA focusing on AJ partici-
pants. All diagnostic procedures for data collection were
identical. Potentially affected individuals and their par-
ents were examined in person by a doctoral-level clinical
psychologist (clinical examiner) and were asked for a
blood sample. Examiners were blind to the subject’s di-
agnosis; they did not knowwhether the family was being
assessed for the study of BP or SZ/SZA. Most of the
subjects were seen in their homes. Detailed clinical meth-
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ods are available from prior publications (Fallin et al.
2003, 2004).
Demographic and Clinical Characteristics
The BPI analyses include 337 trios from 323 families.
The BPI-affected subjects had an average age (SD) at
onset of years, and 50.6% were female. Re-21.5 7.3
sults reported for SZ/SZA are based on 274 trios from
263 families. Cases had an average age at onset of
years, and 25.8% were female. Of the SZ/19.5 4.5
SZA trios, 57 (21%) had probands with SZA, with an
average age at onset of years, and 33.3%19.3 5.4
were female. Included in our trio data are 14 of the 29
multiplex families with SZ/SZA and 8 of the 22 mul-
tiplex families with BPI that had been included in pre-
vious autosomal linkage scans for these disorders (Fallin
et al. 2003, 2004). Five multiplex families contributed
two trios each to the BPI analysis, and eight multiplex
families contributed two trios each to the SZ/SZA anal-
ysis; no family contributed more than two trios to either
the BPI analyses or the SZ/SZA analyses. Also, 14 fam-
ilies were “mixed”—that is, they contained both BPI-
and SZ/SZA-affected subjects—but only the appropriate
subject (proband with BPI for BPI analyses and proband
with SZ/SZA for the SZ/SZA analyses) and his/her par-
ents were included in either the SZ/SZA or BPI analyses.
Of the BPI-affected cases, 66.7% had psychosis.
Ancestry questionnaires were completed for each pro-
band to establish the country or region of origin of all
four grandparents and to reduce the possibility of in-
clusion of non-AJ founders in our sample. Families were
excluded from these analyses if any grandparent of an
affected subject was known to be of non-AJ descent.
Gene Selection
We included candidate genes for BP and for SZ/SZA
because of the emerging evidence for overlap in the ge-
netic etiologies of these disorders. We chose candidate
genes on the basis of two criteria: (1) evidence of as-
sociation from previous studies of BP or SZ/SZA or lo-
cation in candidate chromosome regions identiﬁed in
previous linkage studies of BP or SZ/SZA, and (2) bi-
ological plausibility, including the presence of genes in-
volved in neurodevelopment, in synaptic vesicle func-
tion, in antipsychotic drug metabolism, or in particular
neurotransmitter systems (glutamatergic, serotonergic,
dopaminergic, noradrenergic, GABAergic, or choliner-
gic). The genes we selected were located on 11 chro-
mosomes (see table 1). Fourteen positional candidate
genes in chromosome 22q11.21 (see table 1) were se-
lected on the basis of their location in a candidate chro-
mosomal region, as determined by linkage analysis, and
because they are critically mapped within the boundaries
of the typical ∼3-Mb deletion common in velocardio-
facial syndrome (VCFS [MIM #192430]) (Driscoll et al.
1992; Lindsay et al. 1995; Edelmann et al. 1999), which
has been associated with an increased risk of SZ
(Shprintzen et al. 1992; Pulver et al. 1994b).
SNP Selection and Quality Control
We selected SNPs on the basis of public information
available in August 2003 (dbSNP [genome build 33]).
We initially selected 576 SNPs in and around our can-
didate genes, on the basis of the following criteria, in
order of importance in our selection scheme: (1) known
heterozygosity and minor allele frequency (MAF) 1 0.05,
(2) submission to dbSNP by more than one source, (3)
validation reported, and (4) a minimum density of 1 SNP
per 25 kb. Available nonsynonymous changes located in
coding regions were also included when space on the
array permitted. SNPs were preliminarily screened via a
proprietary algorithm (Illumina) that predicts perfor-
mance on the Illumina platform. The ﬁnal set contained
22 coding SNPs, 12 nonsynonymous and 10 synony-
mous changes.
Genotyping
Genotyping was performed by Illumina, through use
of their Integrated BeadArray System. We supplied Il-
lumina with 22 96-well barcoded DNAmicrotiter plates
containing 2,024 samples of DNA (4 mg) quantiﬁed with
Pico Green to be at 100 ng/ml. Illumina delivered
1,165,824 genotypes, each with a quality score calcu-
lated by proprietary Illumina algorithms (GC_Score).
GC_Score histograms, allele and genotype frequency es-
timation, and Hardy-Weinberg equilibrium (HWE) dis-
tribution testing were completed in SAS (v. 8.02) soft-
ware scripts, with use of available parental data for all
AJ probands with SZ/SZA or BPI (1,210 AJ parents).
Of 2,024 DNA samples, 59 failed to amplify, 11 failed
a sex screen with the use of X- and Y-linked polymor-
phisms, and 3 pedigrees hadMendelian incompatibilities
that could not be resolved; all were dropped from sub-
sequent analyses. Ultimately, we included data from a
total of 337 BPI trios and 274 SZ/SZA trios.
Of the 576 SNPs attempted, 531 (92%) returned ge-
notype calls. Of these 531, 64 were discarded (22 were
monomorphic, 4 had signiﬁcant departures from HWE
at the level among parents, and 38 hadP ! .01
). Across all SNP genotypes, the GC_ScoreMAF ! 5%
ranged from to 0.95, with a mean (SD) of61.0# 10
. From the distribution across all genotype0.80 0.11
calls, we chose a conservative threshold of 0.70 for
inclusion of a genotype in our analyses, to minimize
genotype error in our results. The resulting mean
GC_Score was ; minimum p 0.70, maxi-0.84 0.06
mump 0.95. Thirty-seven SNPs had a mean GC_Score
below this threshold and were not included. Thus, a total
Table 1
64 Candidate Genes for BPI and SZ and Suggestive SNP and Haplotype Results
Gene
Symbol Region
Length
(kB) Exons
SNPs
Attempted
SNPs
Typed SNPs/kB
Median
D′
Median
r2
LD
Blocks
Block
Coveragea
Highly
Suggestiveb Suggestiveb
RGS4 1q23.3 8 5 4 3 1.9 1.00 .36 1 .95 SZc …
DISC1 1q42.1 414 13 22 19 20.7 .16 .00 10 .46 … …
DRD3 3q13.3 50 7 5 5 8.4 .88 .30 1 .55 … …
DRD1 5q35.1 4 3 5 2 1.3 1.00 .99 1 .36 … …
DTNBP1 6p22.3 140 10 16 16 8.3 1.00 .05 4 .59 … BP, SZ/SZA
SCA1 6p23 462 9 24 23 19.3 .12 .00 14 .25 SZ/SZA …
KIF13A 6p23 227 38 15 13 16.2 .97 .34 2 .72 … BP
SynGAP1 6p21.32 37 19 3 1 18.7 … … … … … …
GRM4 6p21.3 112 10 13 6 16.0 .61 .08 3 .24 BP, SZ/SZA …
FKBP5 6p21.31 163 12 7 5 27.2 1.00 .58 1 .34 … …
TFAP2B 6p12.3 26 7 4 4 5.1 1.00 .12 1 .77 … …
GRM3 7q21 221 5 11 10 20.1 .77 .15 3 .78 BP …
NAT1 8p22 53 17 5 2 17.7 .04 .00 2 NA … …
PPP3CC 8p21.3 100 13 10 9 10.0 .97 .88 2 .86 … …
NEF3 8p21.2 7 3 4 1 3.5 … … … … … …
NEFL 8p21.2 6 5 4 3 1.4 1.00 .10 1 7.17 … …
GNRH1 8p21.2 7 3 5 3 1.8 1.00 .17 1 .34 … …
DPdYSL2 8p21.2 144 14 8 8 16.0 .65 .08 4 .57 SZ/SZA BP
ADRA1A 8p21.2 117 2 11 8 13.0 .32 .02 4 .33 … SZ/SZA
CHRNA2 8p21.2 18 8 5 4 3.7 .94 .10 3 .01 … …
PNOC 8p21.1 26 4 7 7 3.3 1.00 .09 1 .67 … SZ/SZA
NRG1 8p12 1,128 12 15 12 86.8 .26 .01 6 .04 … …
CHRNB3 8p11.21 40 6 5 4 8.0 1.00 .23 1 .88 … …
PPP3CB 10q22.2 59 14 4 3 14.8 1.00 .77 1 .64 … …
MYOZ1 10q22.2 10 6 3 1 5.1 … … … … … …
NRG3 10q23.1 1,112 10 23 18 58.5 .14 .01 10 .12 … SZ/SZA
GRID1 10q23.2 767 13 40 29 25.6 .21 .01 13 .31 SZc BP, SZ/SZA
SNCG 10q23.2 54 5 7 5 9.1 .11 .01 4 .01 … …
HTR7 10q23.31 117 4 9 8 13.0 1.00 .04 2 .84 … …
LGI1 10q23.33 40 8 7 5 6.7 .34 .04 4 .02 … SZ/SZA
INA 10q24.33 13 3 5 3 3.3 .97 .88 1 .81 … …
GFRA1 10q26 212 9 15 12 16.3 .24 .02 5 .44 … SZ/SZA
DRD4 11p15.5 3 4 3 1 1.7 … … … … … …
DRD2 11q23 66 7 8 5 11.0 .95 .21 1 .48 … …
GRIN2B 12p12 419 13 34 31 13.1 .22 .02 10 .51 BP …
DAO 12q24 42 11 5 5 7.0 .89 .26 2 .27 BP …
NOS1 12q24 244 29 10 9 24.4 .49 .07 4 .20 SZ/SZA BP
HTR2A 13q14.2 65 4 9 9 6.5 .29 .01 4 .61 … SZ/SZA
SLC15A1 13q32.2 69 21 7 7 8.6 .72 .03 3 .28 … SZ/SZA
ZIC2 13q32.3 5 3 4 3 1.2 1.00 .18 1 .64 … …
TPP2 13q33.1 82 29 6 6 11.8 1.00 .25 1 .73 … SZ/SZA
G30/G72 13q33.2 25 4 15 14 1.7 .96 .15 2 1.33 … BP, SZ/SZA
IL17R 22q11.1 26 13 4 2 8.5 1.00 .56 1 .07 … …
TUBA8 22q11.21 69 5 5 2 22.9 .53 .03 2 NA BP …
DGCR6 22q11.21d 6 6 3 1 3.2 … … … … … …
PRODH 22q11.21d 24 15 11 6 3.4 .66 .03 4 .07 … SZ/SZA
DGCR14 22q11.21d 14 10 6 5 2.4 .94 .17 2 .65 … …
GSCL 22q11.21d 1 3 3 1 .6 … … … … … …
UFD1L 22q11.21d 30 12 5 5 4.9 1.00 .12 1 .73 … …
COMT 22q11.21d 28 6 10 7 3.5 .87 .36 3 .73 … …
DGCR8 22q11.21d 65 14 7 3 16.2 .94 .12 1 .89 … BP
RTN4R 22q11.21d 27 1 6 4 5.4 .69 .42 2 .07 … …
DGCR6L 22q11.21d 6 5 1 1 2.9 … … … … … …
ZNF74 22q11.21d 21 6 4 3 5.2 .96 .46 1 .51 … …
PCQAP 22q11.21d 80 18 9 6 11.4 1.00 .20 1 .68 … …
PIK4CA 22q11.21d 131 54 10 6 18.8 1.00 .67 1 .67 … …
SNAP29 22q11.21d 32 5 5 4 6.4 1.00 .98 1 .98 … …
UBE2L3 22q11.21d 56 1 5 2 18.8 1.00 1.00 1 .30 … …
CABIN1 22q11.23 167 37 9 7 20.9 .99 .46 1 .75 … BP
YWHAH 22q12.3 13 2 9 8 1.5 1.00 .35 2 1.23 … BP
IL2RB 22q13.1 74 10 15 7 9.2 .26 .01 4 .09 BP …
PRKCABP 22q13.1 19 13 10 5 3.1 1.00 .28 1 .84 … …
BZRP 22q13.2 12 4 8 6 1.7 1.00 .26 1 .99 … SZ/SZA
MLC1 22q13.33 27 12 10 7 3.3 .94 .09 2 .93 … …
Total or Average … 7,849 10.5 580 440 11.6 .75 .25 2.91 .66 … …
a Fraction of gene length covered by blocks deﬁned by genotyped SNPs. Some fractions exceed 1 because the entire gene is within a larger block. NA indicates
no blocks deﬁned in that gene.
b Genes were considered highly suggestive if any SNP or haplotype nominal P value was !.01 and suggestive if ..01 ! P ! .05
c Finding was for analyses restricted to only SZ diagnosis.
d Located in the VCFS critical deletion region.
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of 435 (75.6%) of the original 531 Illumina-generated
SNPs were useful for our ﬁnal analyses. We also geno-
typed ﬁve SNPs on chromosome 22q11.21, by use of
TaqMan (Applied Biosystems) assays in our own labo-
ratories: two (rs2016118 and rs3788287) in PRODH,
and three (rs165599, rs3788319, and rs4633) inCOMT.
For all 440 SNPs, we detectedMendelian inconsistencies
by use of PedCheck (O’Connell and Weeks 1998). Ge-
notypes for SNPs with incompatibility for any pedigree
were deleted for that pedigree. Only 73 (0.0082%) of
the 890,560 genotypes analyzed were omitted because
of violation of Mendelian patterns of inheritance.
During the course of our analysis, we identiﬁed un-
recognized microdeletions in the chromosome 22q11
VCFS critical region in one individual with SZ and in
one individual with SZA, on the basis of their observed
non-Mendelian incompatibilities. Both microdeletions
were conﬁrmed by FISH. Speciﬁc attention to this pos-
sibility is necessary when SZ genetic association in this
region is considered. These families were not included
in the chromosome 22q11 candidate-gene analyses for
those SNPs showing this incompatibility. The families
were included in all other candidate-gene analyses.
Graphical and Statistical Analyses
We measured pairwise linkage disequilibrium, using
D′ and , and we used the program Haploview to gen-2r
erate graphical representations of the marker-to-marker
disequilibrium and underlying haplotype block structure
(Barrett et al. 2005). Both single-SNP and haplotype-
based transmission/disequilibrium test (TDT) analyses
were performed, since the value of SNPs versus haplo-
types as markers for an underlying susceptibility allele
depends on the nature of that allele in a particular setting
and on the polymorphisms genotyped. In some situa-
tions, a single SNP will be the best marker of an asso-
ciation (e.g., with the risk variant), whereas in2r p 1
other situations, a haplotype will provide the best in-
formation (e.g., between the risk variant and a2r p 1
particular multi-SNP haplotype).
For single-SNP TDT analyses, including odds ratio
(OR) estimation and calculation of global likelihood ra-
tio test (LRT) P values, we used the genotypic TDT
method, employing conditional logistic regression as im-
plemented in the gtrr function of the GenAssoc STATA
package made available by David Clayton (see David
Clayton’s Web site). We then performed 10,000 per-
mutations of case-pseudocontrol status (with use of the
permute function written for STATA by David Clayton),
ran gtrr on each permuted data set, and calculated em-
pirical P values for each SNP on the basis of 10,000
permutations.
Haplotype TDT analyses were performed using FBAT
software for haplotype data (Horvath et al. 2001) Em-
pirical global P values were obtained using 10,000 per-
mutations, as implemented in FBAT. We delineated sets
of SNPs for haplotype analysis in two ways: (1) creating
two-, three-, and four-SNP windows tiled across each
chromosome and (2) deﬁning haplotype blocks of link-
age disequilibrium (LD) according to the “solid spine of
LD” approach, which requires all pairwise D′ values
within the spine to be 0.75. Currently, it is not clear
which method best exploits themultimarker information
in haplotypes (Schwartz et al. 2003). To maximize our
information, we used both strategies. SNP haplotype
windows were allowed to cross intergene gaps if the
distance between genes was !1 Mb. This occurred for
24 intergene regions.
There are many ways to prioritize ﬁndings for inter-
pretation and follow-up. Because of the varying prior
evidence of association among these candidate genes and
given a diverse correlation structure across SNPs, there
is not a straightforward approach to correct for the com-
plicated multiple testing in this study. We chose to rank
results for each diagnosis separately by empirical P val-
ues at the single-SNP and haplotype levels. We then pri-
oritized genes with haplotype or SNP empirical P values
at the .05 and .01 levels as showing “suggestive” and
“highly suggestive” evidence, respectively, for further
consideration.
Results
Descriptive Analyses
The candidate genes and their characteristics, SNP
density, and LD information are provided in table 1.
Gene sizes had a range from 1.3 kB to 1.13 Mb, and
SNPs per gene had a range of 1–31 SNPs, with an av-
erage of 6.9 SNPs per gene and an average density of 1
SNP per 11.9 kB. The SNPs and their locations on
dbSNP build 33,MAF, genotyped frequencies, andHWE
P values are given in a tab-delimited ASCII ﬁle (online
only) that can be imported into a spreadsheet. Of the
64 genes initially queried, 55 had at least 3 informative
SNPs from the ﬁnal set of 440 SNPs. The average het-
erozygosity across all 440 SNPs was 0.38, with an ap-
proximately uniform distribution of MAF (see ﬁg. A1
[online only]), which provides conﬁdence that our SNP
selection criteria yielded informative SNPs.
To summarize LD information within each gene, we
calculated the median value for pairwise D′ and be-2r
tween SNPs in each gene; the average across genes was
, (table 1). We identiﬁed a total of′ 2D p 0.75 r p 0.25
171 LD blocks. We considered SNPs that were not part
of an LD block with other SNPs in the data set to be a
separate block of size 1 (69 of 171 were “orphan”
SNPs). Of the 102 blocks with more than one SNP, the
average length was 27.7 kB, with a range from 153 bp
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Figure 1 SNP and haplotype results for BPI trios. Empirical P values from genotype TDT and HBAT analyses are plotted on the basis
of 10,000 permutations. Circles, SNP results. Bold lines, 4-SNP haplotype windows. The corresponding genes are labeled for any result with
a P value !.05, and OR estimates are provided for any SNP results with P value !.01. For ease of illustration, 4-SNP haplotype windows are
plotted by reﬂecting only the best haplotype signal (of 4 possible windows) for each SNP.
to 163.7 kB (table 1). The average number of blocks per
gene was 2.9, with a range of 1–14 blocks per gene,
according to the “solid spine” of criterion.′D 1 0.75
Graphs of pairwise LD values and haplotype block de-
lineations for each gene are available in ﬁgure A2 (online
only).
Association Analyses
P values for the TDT and haplotype analyses for BPI
and for SZ/SZA for all 440 SNPs are shown in ﬁgures
1 and 2. Of 387 single SNPs, 24 (6.2%) were signiﬁcant
at the .05 level (after removal of one of each SNP pair
with [53 SNPs]), and 8 (2.1%) were signiﬁcant2r p 1
at the .01 level among the BPI trios, which suggests that
there is not gross inﬂation of false-positive results from
speciﬁed type I error levels. For the SZ/SZA sample, 23
(5.8%) of 399 SNPs were signiﬁcant at the .05 level,
and 5 (1.3%) were signiﬁcant at the .01 level.
The genes with haplotype or SNP ﬁndings that met
our “highly suggestive” criterion among BPI trios were
DAO, IL2RB, GRM3, GRM4, GRIN2B, and TUBA8
(see table 1 and ﬁg. 3). For the SZ/SZA analyses, the
highly suggestive genes were SCA1, GRM4, DPYSL2,
and NOS1. Because of concerns regarding heterogeneity
in phenotype and genetic etiology between SZ and SZA,
we performed analyses restricted to only trios with SZ
subjects. There were no substantial differences from the
combined SZ/SZA analysis, with the exception of RGS4
and GRID1, which both show highly suggestive asso-
ciations only among SZ trios, although similar trends
are seen for the combined group. P values for the three
suggestive RGS4 SNPs among the SZ samples are
, , and , versus ,Pp .006 Pp .019 Pp .007 Pp .089
, and , respectively, for the SZ/SZAPp .120 Pp .096
combined sample (ﬁg. 3). For GRID1, two SNPs and
one 4-SNP haplotype window achieved amongPp .01
the SZ-only sample (ﬁg. 3).
In addition, we compared association ﬁndings be-
tween BPI and SZ/SZA trios because aspects of the SZ/
SZA and BPI phenotypes overlap. Also, there is emerging
evidence of shared linkage and association signals for
the two disorders (Maziade et al. 2005). Only one gene
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Figure 2 SNP and haplotype results for SZ/SZA trios. Empirical P values from genotype TDT and HBAT analyses are plotted on the
basis of 10,000 permutations. Circles, SNP results. Bold lines, 4-SNP haplotype windows. The corresponding genes are labeled for any result
with a P value !.05, and OR estimates are provided for any SNP results with P value !.01. For ease of illustration, 4-SNP haplotype windows
are plotted by reﬂecting only the best haplotype signal (of 4 possible windows) for each SNP.
met our highly suggestive criterion for both disorders—
GRM4, on chromosome 6, which had a highly sugges-
tive SNP result for both BPI and SZ/SZA, although a
different SNP was associated with each disorder and
these are not in LD with each other (ﬁg. 3). Five addi-
tional genes showed associations at the suggestive lev-
el for both disorders: DTNBP1, DPYSL2, G30/G72,
GRID1, and NOS1. Candidate gene ﬁndings for BP and
SZ/SZA, in the context of previous reports, are sum-
marized in ﬁgure 4.
Known functions of the protein products of the highly
suggestive and BPI-SZ/SZA overlapping genes are shown
in table 2. Although genes were chosen for involvement
in one of several neurotransmitter systems, the majority
of genes among the highest ranks are involved in glu-
tamatergic signaling pathways. This is consistent with
previous implications of the glutamatergic signaling
pathways in BPI and SZ (Harrison and Weinberger
2005; Owen et al. 2005).
Discussion
We have performed a screen of 64 region-speciﬁc or
previously reported candidate genes for BPI and SZ/SZA
disorders among AJ case-parent trios. We report six
genes that meet our highly suggestive criterion for BPI
association and four that meet this threshold for SZ/
SZA. In addition, two genes meet the highly suggestive
criterion only among SZ trios. Whereas only one gene
met our highly suggestive criterion in both disorders,
ﬁve others showed evidence at the suggestive level in
both disorders, which may indicate that the genetic as-
sociation is important for a subgroup of the affected
individuals in each of the diagnostic categories. The sub-
group may be associated with or deﬁned by the presence
of one or more of the overlapping clinical features (i.e.,
mania or psychosis).
This work has attempted to minimize several limi-
tations often plaguing association studies in psychiatry.
First, to minimize genetic heterogeneity, we have fo-
cused on cases of AJ descent. Although our sample may
contain multiple susceptibility genes or alleles, we hy-
pothesize that founder alleles will be a more common
source of risk among AJ cases, thereby increasing our
ability to detect gene effects. Founder effects have been
described elsewhere for both monogenic and complex
traits in the AJ population (Neuhausen et al. 1998; Stern
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et al. 2001; Rennert et al. 2002; Niell et al. 2003; Sug-
imura et al. 2003). Second, in an effort to minimize
misclassiﬁcation and phenotype heterogeneity, we have
employed skilled diagnosticians and clinical consensus,
have restricted the BP phenotype to the most severe and
reliable diagnosis, and have considered SZ separately
from SZA. Third, we have achieved greater gene cov-
erage than previously reported for most of these can-
didate genes. We aimed to cover each gene as adequately
as possible at the time of design, in accordance with
available information, technology, and funding. Across
these 64 genes, 58 had at least two SNPs genotyped and
55 had at least three SNPs, with an average of 6.9 SNPs
per gene, an average density of 1 SNP/11.9 kB within
genes, and 66% of each gene, on average, covered by
LD blocks detectable with the SNPs genotyped. This is
also one of the largest reported sets of SNP genotypes
for AJ individuals, and these LD ﬁndings provide val-
uable information about LD in candidate genes for this
population. With the use of an average SNP density of
11.9 kB, the mean block size was found to be 27.7 kB,
which is slightly greater than that observed for more-
outbred populations (Gabriel et al. 2002).
Prioritization
To analyze this large set of candidate gene SNPs, we
used both single-SNP and haplotype-basedmethods.The
comparable utility of these two methods is still debated
and depends on whether the true risk allele is in higher
LD with a single SNP or with a multi-SNP haplotype.
Single-SNP analysis can be more statistically efﬁcient if
the former is true; however, there are many examples in
which haplotypes provide more information than any
single SNP genotyped. This will certainly depend on SNP
density and LD in the region. Given the nature of this
SNP study with varying densities and LD structures, it
is important to pursue both methods. There are also
many choices regarding the implementation of haplotype
analyses. We chose a systematic approach of using slid-
ing windows as well as haplotype sets deﬁned by the LD
structure in a gene. The former has the advantage of not
relying heavily on a blocking algorithm, whereas the
latter exploits LD speciﬁc to its structure. In our highest-
ranked genes (see ﬁg. 3), the sliding windows and block
ﬁndings are similar.
This set of 440 SNPs introduces a challenge for mul-
tiple testing correction, as there is not a straightforward
correction for these highly correlated tests, some of
which are speciﬁc replications, and all of which are based
on prior evidence of some kind. One suggested approach
has been to identify the number of pseudoindependent
signals within the data set through principal components
analysis or the number of LD blocks (Nicodemus et al.
2004; Nyholt 2004). With the assumption that the 171
blocks represent independent information, an approxi-
mate correction may be for ex-ap .05/171p 0.0003
perimentwide signiﬁcance at the level. Onlyap 0.05
one SNP (in TUBA8) and no haplotypes met this strict
criterion for BPI, and only one SNP and one haplotype
block reached this level for SZ/SZA (both in NOS1).
Another suggestion would be to consider ranked P val-
ues and to estimate the false discovery rate for a deter-
mined threshold of P values. This method does not work
well in the case of highly correlated tests, such as our
candidate gene SNP approach (Efron 2004). To best in-
terpret our results, we chose instead to rank our ﬁndings
according to uncorrected empirical P values, with the
realization that this method may include false positive
results. However, most of these genes were included in
this screen because of prior linkage or association reports
and biological plausibility. The ultimate proof of asso-
ciation will be the consistent replication by several
groups and in several populations and the identiﬁcation
of functional variants.
Genes Implicated in BPI
Genes achieving our highest ranks include some pre-
viously associated with this disorder as well as some new
association ﬁndings (see ﬁg. 4). DAO, which interacts
with glutamate pathways, met our highly suggestive cri-
terion among BPI trios and has been previously asso-
ciated with both BPI and SZ risk (Chumakov et al. 2002;
Schumacher et al. 2004). Our BPI-associated haplotypes
overlap with the Schumacher et al. (2004) BP haplotype
(rs3741775 in common) and the Chumakov et al. (2002)
single-point SZ ﬁnding (rs3741775 and rs3918347 in
common). The ﬁve additional genes meeting our highly
suggestive criteria for BPI have not previously been re-
ported to be associated with BP. These include two glu-
tamate receptors (GRM3 and GRM4) and a glutamate
receptor-related gene (GRIN2B), as well as two genes
in the chromosome 22q11-13 SZ/SZA/BP region
(IL2RB and TUBA8). Positive associations forGRIN2B
have been reported for SZ (Ohtsuki et al. 2001a; Di
Maria et al. 2004), but not for BP. GRM4, located in a
SZ linkage region on chromosome 6p21, has also been
associated with SZ (Ohtsuki et al. 2001b), but not with
BP. TUBA8, located immediately proximal to the ∼3-
Mb VCFS critical region on chromosome 22q11 (Stanchi
et al. 2000), is a positional candidate, based on reported
psychiatric disorders shown in VCFS-deleted patients.
Finally, IL2RB, located more distally to the VCFS re-
gion, at chromosome 22q13, is involved in T-cell–me-
diated immune responses.
Genes Implicated in SZ/SZA
Among the six highly suggestive SZ/SZA or SZ-only
genes, ﬁve conﬁrm previous associations (RGS4, SCA1,
GRM4, DPYSL2, and NOS1), and one can be consid-
ered a new association report (GRID1). Our strongest
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Figure 4 Candidate gene ﬁndings for BP and SZ/SZA in the context of previous reports. Top, Genes shown in bold have P values !.01
for any SNP or haplotype. Bottom, Genes have P values !.05 for any SNP or haplotype. Genes in brackets have P values !.05 for both BPI
and SZ/SZA. Because ﬁndings with P values in the .01–.10 range may reﬂect lack of power rather than lack of replication, we have tabulated
only genes that did not provide evidence for association at even a liberal level.P ! .10
associations for SZ/SZA are for two SNPs (rs3782219
and rs3782221) 7.6 kb apart ( ) in NOS1′D p 0.95
( and , respectively). A SNP inPp .0003 Pp .0014
NOS1 was previously shown elsewhere to be highly sig-
niﬁcant in a Japanese case-control study (Shinkai et al.
2002), although that SNP is 135 kb centromeric to our
ﬁndings in this gene and was not signiﬁcant in our anal-
ysis. It is, nonetheless, encouraging that two distinct pop-
ulations show association for this gene, and it is not
surprising that particular markers do not give similar
results. Variants inRGS4 have been associatedwith both
SZ/SZA and BP risk (Chowdari et al. 2002). A 4-SNP
haplotype localized to a 10-kb region of the gene has
been conﬁrmed in an Irish sample (Morris et al. 2004;
Williams et al. 2004). Our positive SZ association (omit-
ting the SZA probands) includes one of those SNPs
(rs951439) and another SNP ∼7 kb centromeric
(rs2344671). SCA1 is of interest because of its role in
spinocerebellar ataxia, type 1 (MIM 164400), a neu-
rodegenerative disorder with ataxia, dysarthria, and pro-
gressive bulbar dysfunction associated in some patients
with mild cognitive dysfunction (Zoghbi et al. 1991),
and variants in SCA1 have been associated with SZ
(Wang et al. 1996a). Previous association for DPYSL2
with schizophrenia used a Japanese case/control popu-
lation and found support for the 2236TrC polymor-
phism and a 2-SNP haplotype (1506T-*2236C) (Nakata
et al. 2003a). Although we did not genotype these SNPs,
our associated haplotype spans the 1506T polymor-
phism, within 1.1 kb of the 2236C polymorphism.
Finally,GRID1met our criterion for highly suggestive
association with SZ, but it has not been previously re-
ported as a risk factor for SZ or BP. SNPs and/or hap-
lotypes in this gene were also suggestive of association
with BPI and SZ/SZA combined. GRID1 is located 1.35
Mb from our peak chromosome 10q22-q23 SZ/SZA
linkage signal among AJ families (D10S1774) (Fallin et
al. 2003). This gene and its closest paralog, GRID2,
encode two members of a subfamily of the glutamate
ionotropic receptors; both were identiﬁed by sequence
similarity with other glutamate receptors, but no ligand
has yet been conﬁrmed for either. In mice, mutations in
GRID2 are responsible for cerebellar dysfunction (Se-
limi et al. 2003; Wang et al. 2003).
BPI and SZ
Several recent reports of linkage and association over-
lap between BP and SZ motivate closer consideration of
possible similarities in associations between BPI and SZ/
SZA among our samples. Whereas GRM4 is the only
highly suggestive gene in common between the BPI and
SZ/SZA studies, ﬁve additional genes have overlapping
evidence of suggestive SNP or haplotype associations for
both disorders. Only G30/G72 has previously been as-
sociated with both disorders (Hattori et al. 2003). The
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Table 2
Known Functions of 13 Candidate Genes Showing Highly Suggestive Association or
Overlapping BPI/SZ Association
Gene
Symbol Gene Name
Known Biological
Systems
DTNBP1 Dystrobrevin-binding protein 1 Glutamate
GRID1 Glutamate receptor, ionotropic, delta 1 Glutamate
GRM3 Glutamate receptor, metabotropic 3 Glutamate
GRM4 Glutamate receptor, metabotropic 4 Glutamate
NOS1 Nitric oxide synthase 1 (neuronal) Glutamate, dopamine
DAO D-amino acid oxidase Glutamate, NMDA
G30/G72 D-amino acid oxidase activator (DAOA) Glutamate, NMDA
GRIN2B Glutamate receptor, ionotropic, NMDA 2 Glutamate, NMDA
RGS4 Regulator of G-protein signaling proteins Glutamate, signal transduction
DPYSL2 Dihydropyrimidinase-like 2 Neurodevelopmental
SCA1 Spinocerebellar ataxia 1 (ATXN1) Neurodegenerative repeat
IL2RB Interleukin 2 receptor, beta Immune response
TUBA8 Alpha tubulin, peroxisome biogenesis factor 26 Cell cytoskeleton
others are from various locations and have various func-
tions, including glutamatergic, dopaminergic, and neu-
rodevelopmental roles.
Relationship with Previous Findings
To summarize our results in the context of previous
association studies, in ﬁgure 4 we show previous asso-
ciations supported by our ﬁndings, as well as genes for
which we found no support ( ) for previous as-P 1 .10
sociations. None of the dopamine receptor genes showed
SNP or haplotype P values !.10 among the BPI trios,
despite consistent previous associations (Spurlock et al.
1998; Jonsson et al. 2003). The same is true for DISC1,
RGS4, and PIK4CA, although these genes have been
less consistently replicated for association with BP in
previous studies. Many of the previously associated SZ
genes did not show association in our AJ families. This
may indicate that these genes are less important in the
genetic predisposition to SZ/SZA among individuals of
AJ descent, or it could reﬂect a lack of power to detect
subtle associations. Most notably, we observed no as-
sociation with COMT, despite previous ﬁndings in AJ
samples from Israel (Shifman et al. 2002) with several
overlapping SNPs between the two studies (Shifman et
al. 2002), including the functional val/met polymor-
phism (rs4680). This may be due, in part, to differences
in the diagnostic exclusion criteria between the studies—
that is, individuals diagnosed with SZA were excluded
from the Shifman et al. (2002) study, but not from our
study. Our analyses excluding SZA may not have had
sufﬁcient power to detect the association.
Genes were initially chosen for our study on the basis
of biological plausibility, including their involvement in
one of several neurotransmitter systems. Interestingly,
the great majority of genes among the highest ranks are
involved in the glutamatergic pathway. Three of the BPI-
associated genes encode glutamate receptors, including
both ionotropic (GRIN2B) and metabotropic receptors
(GRM3 and GRM4) (Hollmann et al. 1994), whereas
another (DAO) is involved in the regulation of glutamate
receptor signaling. DAO is a major enzyme that controls
the breakdown of D-amino acids such as D-serine,which
has been shown to be a cotransmitter for the NMDA
type of glutamate receptors (Mothet et al. 2000; Bar-
anano et al. 2001), and, thus, DAO and G30/G72,
which is a DAO activator, may regulate NMDA receptor
function. For example, DAO-knockout mice have re-
cently been reported to have defects in NMDA receptor
signaling (Hashimoto et al. 2005). In addition, several
genes associated with SZ/SZA are related to glutama-
tergic signaling. GRID1 is highly related to ionotropic
glutamate receptor subunits (Hollmann et al. 1994), al-
though the ligand for the GRID1 gene product has not
been identiﬁed. Also, RGS4 regulates, and NOS1 is reg-
ulated by, glutamatergic signaling. The activation of sev-
eral types of glutamate receptors has been shown to
regulate nNOS activity (coded by NOS1) (Bredt and
Snyder 1989; Snyder and Bredt 1991), whereas RGS4
has been shown to inhibit metabotropic glutamate re-
ceptor function (Saugstad et al. 1998). These results are
consistent with recent ﬁndings implicating a potential
disruption of excitatory synaptic function in SZ (Har-
rison and Weinberger 2005; Owen et al. 2005), and they
suggest that genes involved in glutamatergic signaling
pathways are promising candidates for an exhaustive
study of genes associated with BPI and SZ/SZA.
Limitations
Despite the strengths of this study, several issues and
limitations must be considered. First, although we have
achieved adequate SNP coverage for many genes (see ﬁg.
A1 [online only] and ﬁg. 4), gaps still exist, with the
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biggest gene having coverage as sparse as 1 SNP/87 kB
(NRG1 [1.128 Mb]). This project was developed before
the vast majority of HapMap data were available and,
therefore, it relied on dbSNP, Celera, and Perlegen
marker information at the time. These gaps can now be
improved according to Caucasian marker and LD in-
formation for these genes in the HapMap project, as-
suming the Caucasian samples (families from Utah) used
in HapMap are representative of the AJ population.
Second, we selected candidate genes in accordance
with their prior association or location within a previ-
ously reported linkage region. Since there are many link-
age regions, we prioritized linkage among AJ samples,
such as our own SZ genome scan (Fallin et al. 2003) or
linkage evidence from meta-analyses. Because of efﬁ-
ciency and budget constraints, some important regions
were not considered, such as 2q, 6q, and 18q. These
regions were of lower priority for this project because
of the overlapping work of our collaborators and
colleagues.
Third, although 337 and 274 case-parent trios are
currently among the largest trio collections for BPI and
SZ/SZA, respectively, small effect sizes, or marginal ef-
fects when interaction exists, may still be difﬁcult to
detect. For example, although our smaller data set (the
SZ/SZA sample) provides 96% power to detect an
for a marker with 10% risk allele frequencyORp 2.5
in complete LD with the actual risk variant (assuming
0.0003 type I error rate), power to detect an OR of 1.5
is dramatically reduced (to 7%) under this same scenario
(Gauderman 2002). Our inability to replicate some pre-
vious ﬁndings should be considered in this context.
Fourth, our focus on case-parent trios may result in
a slightly different sample of cases than in other genetic
studies that focused on either multiply affected families
only or on unrelated cases and controls. We compared
characteristics of the cases reported in this study (who
had parental DNA available) with those of cases we have
collected for other purposes, who did not have parents
available for study (referred to as singletons). For both
BPI and SZ/SZA cases, the cases in trios had a younger
age at onset. In addition, among SZ cases in trios, there
are more men (78% vs. 58%) andmore cases withmanic
episodes (42% vs. 29%), compared with our singleton
cases. This higher proportion of manic episodes may
have contributed to the overlap in ﬁndings between BPI
and SZ in our studies.
These prioritized genes deserve further evaluation to
improve the understanding of their relative importance
in both disorders in the AJ and other populations. They
must be conﬁrmed in other AJ samples, which we are
in the process of collecting. In addition, the importance
of these genes in risk for SZ and BP more generally must
be evaluated in other, non-AJ populations. This geno-
type collection will also allow the evaluation of simul-
taneous effects in a way not previously possible, includ-
ing conditional analyses to understand potential inter-
actions and the relative importance of particular genes
or clinical/environmental risk factors. Also, higher-order
data-mining analyses to discover new hypotheses about
interactions will be important. Further, the focus on par-
ent/child trios will allow detection of parent-of-origin
effects, which may become an important factor as epi-
genetic mechanisms are explored. These will be the foci
of future work.
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